Is Acotiamide available for sale in China?

Acotiamide was first launched in Japan in 2013 and is used to treat postprandial fullness, epigastric bloating and early satiety symptoms caused by functional dyspepsia. After being marketed in Japan, its clinical experience shows that acotiamide can effectively improve patients' gastric motility disorders, relieve discomfort after daily eating, and improve quality of life. In Japan and some Asian markets, acotiamide is regarded as an innovative option for the drug treatment of functional dyspepsia, especially for patients who do not respond well to traditional prokinetic drugs.

In the mainland Chinese market, the original drug acotiamide has not yet been approved for marketing and has not been included in the medical insurance system. This means that patients cannot purchase legal original drugs through regular hospitals or pharmacies. In clinical practice, doctors usually recommend other approved gastric motility drugs to manage symptoms of functional dyspepsia, or participate in clinical studies using acotiamide under scientific research conditions. Due to the lack of domestic marketing authorization, patients who obtain drugs from overseas channels need to pay special attention to the source, storage conditions and dosage specifications of the drugs to ensure safety.

Although it is not yet legally sold in China, acotiamide’s overseas application experience provides an important reference for domestic gastric motility drug treatment. In the future, with the advancement of clinical research and regulatory approval, acotiamide is expected to be approved for marketing in China and become a new option for the treatment of functional dyspepsia. Doctors and patients should pay attention to its potential clinical value and manage symptoms through formal drugs and lifestyle intervention before obtaining legal channels to avoid the risks caused by purchasing drugs on their own. In short, acotiamide is not currently available in China, but its application in Japan and other overseas markets provides reliable reference and clinical experience for the treatment of functional dyspepsia.

Reference: https://www.rad-ar.or.jp/siori/english/search/result?n=33322